Baio Labs obtains funding to accelerate drug discovery with generative AI
EPFL spin‑off Baio Labs has secured CHF 150,000 from Venture Kick to develop its generative AI platform, Drugon, for early‑stage drug discovery. The platform can design novel small molecules for specific therapeutic targets in seconds, potentially reducing the time and cost of identifying drug candidates. The funding will support scaling R&D and go‑to‑market efforts.
EPFL spin‑off Baio Labs has secured CHF 150,000 from Venture Kick to develop its generative AI platform, Drugon, for early‑stage drug discovery. The platform can design novel small molecules for specific therapeutic targets in seconds, potentially reducing the time and cost of identifying drug candidates. The funding will support scaling R&D and go‑to‑market efforts.
The investment demonstrates Switzerland’s growing role in AI‑driven life‑science innovation and supports the development of advanced generative models for drug design within the Swiss biotech ecosystem.
Original source record. Open the original record to verify the underlying announcement.